Literature DB >> 21623239

The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.

Hirotsugu Kenmotsu1, Tateaki Naito, Madoka Kimura, Akira Ono, Takehito Shukuya, Yukiko Nakamura, Asuka Tsuya, Kyoichi Kaira, Haruyasu Murakami, Toshiaki Takahashi, Masahiro Endo, Nobuyuki Yamamoto.   

Abstract

INTRODUCTION: It is unknown what type of interstitial lung disease (ILD) has high risk for chemotherapy-related exacerbation of ILD. We investigated the risk of exacerbation of ILD for patients with lung cancer with ILD.
METHODS: One hundred nine patients with lung cancer with ILD treated with cytotoxic chemotherapy at Shizuoka Cancer Center between August 2002 and April 2010 were retrospectively reviewed.
RESULTS: On pretreatment computed tomography (CT) of the chest, 69 patients (63%) were identified with usual interstitial pneumonia (UIP) pattern, and 40 patients (37%) had non-UIP pattern. Patients with UIP pattern developed cytotoxic chemotherapy-related exacerbation of ILD more frequently than those with non-UIP pattern (30 versus 8%, p = 0.005). The incidence of grade 5 pulmonary toxicities was 9% in patients with UIP pattern, compared with 3% in those with non-UIP pattern. Multivariate analyses demonstrated that age (<70 years) and CT pattern (UIP) were significant independent risk factors for cytotoxic chemotherapy-related exacerbation of ILD. In small cell lung cancer, overall survival (OS) from the start of first-line chemotherapy was significantly shorter in UIP pattern than non-UIP pattern (median OS: 9 versus 16 months, p = 0.0475), whereas there was no significant difference in patients with non-small cell lung cancer (median OS: 12 versus 9 months, p = 0.2529).
CONCLUSIONS: Our results indicated that the incidence of exacerbation of ILD was significantly higher in patients with lung cancer with UIP pattern on CT findings than in those with non-UIP pattern. Therefore, great care is required when administering cytotoxic chemotherapy agents for patients with lung cancer with UIP pattern.

Entities:  

Mesh:

Year:  2011        PMID: 21623239     DOI: 10.1097/JTO.0b013e318216ee6b

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  66 in total

1.  Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

Authors:  Mizuki Nishino; Stephanie Cardarella; Suzanne E Dahlberg; Tetsuro Araki; Christine Lydon; David M Jackman; Michael S Rabin; Hiroto Hatabu; Bruce E Johnson
Journal:  Eur J Radiol       Date:  2015-02-07       Impact factor: 3.528

Review 2.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.

Authors:  Aya Fukuizumi; Yuji Minegishi; Miwako Omori; Kenichiro Atsumi; Natsuki Takano; Kakeru Hisakane; Satoshi Takahashi; Kenichi Kobayashi; Teppei Sugano; Susumu Takeuchi; Rintaro Noro; Masahiro Seike; Kaoru Kubota; Arata Azuma; Akihiko Gemma
Journal:  Int J Clin Oncol       Date:  2019-07-27       Impact factor: 3.402

4.  The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.

Authors:  Naoki Nishiyama; Takayuki Honda; Manabu Sema; Tatsuo Kawahara; Yasuto Jin; Ichiro Natsume; Tomoshige Chiaki; Takaaki Yamashita; Yoshikazu Tsukada; Reiko Taki; Yoshihiro Miyashita; Kazuhito Saito; Tomoya Tateishi; Hiroyuki Sakashita; Yasunari Miyazaki
Journal:  Int J Clin Oncol       Date:  2019-11-13       Impact factor: 3.402

5.  Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Authors:  Yuto Yasuda; Takashi Nomizo; Hiroaki Ozasa; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Tomohiro Handa; Takeshi Kubo; Young Hak Kim
Journal:  Mol Clin Oncol       Date:  2017-08-11

6.  Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia.

Authors:  Takashi Kinoshita; Koichi Azuma; Tetsuro Sasada; Masaki Okamoto; Satoshi Hattori; Youhei Imamura; Kazuhiko Yamada; Morihiro Tajiri; Tsukasa Yoshida; Yoshiaki Zaizen; Akihiko Kawahara; Kiminori Fujimoto; Tomoaki Hoshino
Journal:  Oncol Lett       Date:  2012-06-12       Impact factor: 2.967

7.  A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients.

Authors:  Toshihiko Sato; Haruhiko Kondo; Atsushi Watanabe; Jun Nakajima; Hiroshi Niwa; Hirotoshi Horio; Jiro Okami; Norihito Okumura; Kenji Sugio; Satoshi Teramukai; Kazuma Kishi; Masahito Ebina; Yukihiko Sugiyama; Takashi Kondo; Hiroshi Date
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-10-30

8.  Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease.

Authors:  Hideyuki Niwa; Yoshiro Nakahara; Masanori Yokoba; Hisashi Mitsufuji; Jiichiro Sasaki; Noriyuki Masuda
Journal:  Mol Clin Oncol       Date:  2017-08-03

9.  Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.

Authors:  Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Masashi Kondo; Yoshinori Hasegawa
Journal:  Int J Clin Oncol       Date:  2013-04-17       Impact factor: 3.402

10.  Predictive value of 18F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy.

Authors:  Kimitaka Akaike; Koichi Saruwatari; Seitaro Oda; Shinya Shiraishi; Hiroshi Takahashi; Shohei Hamada; Shinji Iyama; Yuko Horio; Yusuke Tomita; Sho Saeki; Shinichiro Okamoto; Hidenori Ichiyasu; Kazuhiko Fujii; Takuro Sakagami
Journal:  Int J Clin Oncol       Date:  2019-11-28       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.